Chimeric antigen receptor (CAR) T cell therapy, an immunotherapy using gene-modified T cells, has recently made a big success. CAR T cells targeting CD19 is highly effective against B cell malignancies. Next good target for CAR T therapy is multiple myeloma. B cell maturation antigen has been proved to be a good target for CAR T cell therapy in early-phase clinical trials. We are also developing CAR T cells targeting a protein conformation that is preferentially detected in myeloma cells. In this review, I will summarize the state of art in the field of CAR T cell therapy against myeloma, and also present our effort to develop a new CAR T cell therapy.

中文翻译：

---

嵌合抗原受体T细胞治疗多发性骨髓瘤。

嵌合抗原受体（CAR）T细胞疗法是一种使用基因修饰的T细胞的免疫疗法，最近取得了巨大的成功。靶向CD19的CAR T细胞对B细胞恶性肿瘤非常有效。CAR T治疗的下一个好靶点是多发性骨髓瘤。在早期临床试验中，已证明B细胞成熟抗原是CAR T细胞治疗的良好靶标。我们还在开发靶向于在骨髓瘤细胞中优先检测到的蛋白质构象的CAR T细胞。在这篇综述中，我将总结针对骨髓瘤的CAR T细胞疗法领域的最新技术，并介绍我们为开发新的CAR T细胞疗法所做的努力。